Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorZhigang Li
About this trial
The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced Esophageal Squamous Cell Carcinoma.
Eligibility criteria
Qualifiers
The result of pathological biopsy showed esophageal squamous cell carcinoma;
Have not received systemic or local treatment for esophageal cancer in the past;
Age 18-75 years (including 18 and 75 years old), both male and female;
ECOG score 0-1;
Disqualifiers
There are unresectable factors, including unresectable tumors, unresectable contraindications for surgery, or rejection of surgery;
Patients with supraclavicular lymph node metastasis;
Poor nutritional status, BMI <18.5 Kg/m2; if the symptomatic nutritional support is corrected before randomization, the main investigator can continue to consider it after evaluation;
Those who are known to have a history of allergies to the drug components of this program;
Trial design
Treatments tested in this trial
- Camrelizumab
- radiotherapy
Treatment groups
426 Participants
are divided into 3 treatment groupsSponsors and collaborators
Zhigang Li
Lead sponsor
Shanghai Chest Hospital
Sponsor institution
Jiangsu HengRui Medicine Co., Ltd.
Collaborator
Source ClinicalTrials.gov